Last updated July 17, 2026
Key finding
Insulin resistance decreased from 0.89 to 0.77 (p < 0.05).
This study evaluated the effects of Vildagliptin on insulin resistance and weight reduction in newly diagnosed Type 2 Diabetes patients, showing significant improvements in several metabolic parameters.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the effects of Vildagliptin on insulin resistance and weight reduction in newly diagnosed Type 2 Diabetes patients, showing significant improvements in several metabolic parameters.
These findings are clinically significant as they suggest that Vildagliptin may offer better metabolic control for patients newly diagnosed with Type 2 Diabetes. Improved insulin sensitivity and weight reduction can lead to better long-term health outcomes and potentially reduce the risk of diabetes-related complications.
Limited sample size may affect generalizability Short duration of the study may not capture long-term effects No assessment of quality of life or patient-reported outcomes
Published in
Publication details and source links for this paper.
Toka E, Mohamed EAA, Mina N, Dalia Z. Effects of Vildagliptin on Insulin Resistance and Weight Reduction in Newly Diagnosed Type 2 Diabetes. European Journal of Clinical Pharmacology. 2025;81(11):1593-1608. doi:10.1007/s00228-025-03894-8
Insulin resistance decreased from 0.89 to 0.77 (p < 0.05)
HbA1c decreased from 7.65% to 6.3% (p < 0.05)
Body weight decreased by 2.58% (p < 0.05)
AGE levels decreased from 54.5 µg/mL to 44 µg/mL (p < 0.05)
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Dipeptidyl peptidase-4 inhibitors, Gliclazide sustained release and Advanced glycation end products (AGEs), Body weight, HbA1c, and 1 more.
This study contributes evidence to
Primary intervention
Dipeptidyl peptidase-4 inhibitors
Primary outcomes
Primary intervention
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
4
Related topics
8
Evidence pairs
563
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
Related evidence
Evidence relationship
Save evidence
Evidence relationship
Save evidence
Core evidence
The primary outcomes reported in this study.
Dipeptidyl peptidase-4 inhibitors → Advanced glycation end products (AGEs)
Dipeptidyl peptidase-4 inhibitors → Advanced glycation end products (AGEs)
Dipeptidyl peptidase-4 inhibitors → Body weight
Dipeptidyl peptidase-4 inhibitors → Body weight
Dipeptidyl peptidase-4 inhibitors → Insulin resistance
Dipeptidyl peptidase-4 inhibitors → Insulin resistance
Gliclazide sustained release → Advanced glycation end products (AGEs)
Gliclazide sustained release → Advanced glycation end products (AGEs)
Gliclazide sustained release → Insulin resistance
Gliclazide sustained release → Insulin resistance
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on DPP-4 Inhibitors and Body Weight, DPP-4 Inhibitors and HbA1c.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring Body Weight
Measures Body Weight as a key outcome.
All studies on DPP-4 Inhibitors
Contributes to DPP-4 Inhibitors evidence base.
All studies measuring HbA1c
Measures HbA1c as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
3 results
3 results
3 results
3 results
3 results
Generated from the study's connected evidence using Evidence Intelligence™.
DPP-4 Inhibitors appears to improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 79.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 10 supporting studies with consistent results and a positive effect signal.
Limitations
DPP-4 Inhibitors may improve Body Weight.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
Body weight
EvidenceScore™ Strong | EvidenceScore™ 79.0 | moderate positive | ConsistencyScore™ Generally Consistent | 1 study
Why this answer: This answer is based on 7 supporting studies with generally consistent results and a positive effect signal.
Limitations
Sulfonylureas may improve HbA1c.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Ranked evidence signals
HbA1c
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
Sulfonylureas may improve Body Weight.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Ranked evidence signals
Body weight
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
